Skip to main content
Premium Trial:

Request an Annual Quote

Jury Sides with Life Tech in Second Phase of IP Suit with Illumina

NEW YORK (GenomeWeb News) – Life Technologies said today that a jury in the US District Court for the Northern District of California has decided in its favor in the second phase of an ongoing patent-infringement suit with Illumina.

After a seven day trial, the jury unanimously decided that Life Tech's Applied Biosystems SOLiD sequencing technology does not infringe a patent at the heart of the dispute, the company said.

Illumina had alleged that the SOLiD system infringed US Patent Nos. 5,969,119; 5,750,341; and 6,306,597. The court had already ruled in August that ABI does not infringe the asserted claims of the '341 and '597 patents. The jury decision announced today clears ABI of infringing the '119 patent.

Kip Miller, president of the genetic systems division at Life Technologies, said in a statement that the company is "pleased" with the decision, which "validate[s] our belief that the SOLiD sequencing system is unique in its design."

Earlier this month, Illumina won the first phase of the trial, in which the jury found that Illumina owns the patents that are the subject of the suit.

An Illumina spokesperson was not available for comment.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.